Financhill
Sell
44

OCGN Quote, Financials, Valuation and Earnings

Last price:
$0.67
Seasonality move :
0.84%
Day range:
$0.65 - $0.74
52-week range:
$0.52 - $2.06
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
44.77x
P/B ratio:
6.60x
Volume:
3.8M
Avg. volume:
3.6M
1-year change:
-59.88%
Market cap:
$195.6M
Revenue:
$4.1M
EPS (TTM):
-$0.19

Analysts' Opinion

  • Consensus Rating
    Ocugen has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $6.75, Ocugen has an estimated upside of 907.46% from its current price of $0.67.
  • Price Target Downside
    According to analysts, the lowest downside price target is $4.00 representing -497.02% downside risk from its current price of $0.67.

Fair Value

  • According to the consensus of 2 analysts, Ocugen has 907.46% upside to fair value with a price target of $6.75 per share.

OCGN vs. S&P 500

  • Over the past 5 trading days, Ocugen has underperformed the S&P 500 by -12.07% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Ocugen does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Ocugen revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Ocugen reported revenues of $764K.

Earnings Growth

  • Ocugen has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Ocugen reported earnings per share of -$0.05.
Enterprise value:
165.8M
EV / Invested capital:
--
Price / LTM sales:
44.77x
EV / EBIT:
--
EV / Revenue:
40.89x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.64x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-89.71%
Net Income Margin (TTM):
-1333.02%
Return On Equity:
-171.04%
Return On Invested Capital:
-136.46%
Operating Margin:
-1811.52%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue -- $6M $4.1M $1.4M $764K
Gross Profit -- -- -- -- --
Operating Income -$89.1M -$65.5M -$54.8M -$11.5M -$13.8M
EBITDA -$88.6M -$64.8M -$52.8M -$11.3M -$13.2M
Diluted EPS -$0.38 -$0.27 -$0.19 -$0.04 -$0.05
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $25.9M $102.6M $98.5M $43M $61.7M
Total Assets $27.4M $105.8M $108.6M $64.5M $82.4M
Current Liabilities $3.6M $7M $28.5M $17.1M $21.6M
Total Liabilities $5.8M $9.9M $34.7M $24M $52.8M
Total Equity $21.6M $95.8M $74M $40.6M $29.6M
Total Debt $2.1M $1.7M $2.3M $2.8M $28.7M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations -$60.1M -$62.1M -$42.1M -$11.3M -$10.4M
Cash From Investing -$17M $3.1M -$3.4M -$2.7M -$13K
Cash From Financing $59.5M $20.9M $64.9M $16K $30.2M
Free Cash Flow -$64.5M -$72.5M -$45.5M -$14M -$10.4M
OCGN
Sector
Market Cap
$195.6M
$33.9M
Price % of 52-Week High
32.52%
43.63%
Dividend Yield
0%
0%
Shareholder Yield
-18.65%
-0.68%
1-Year Price Total Return
-59.88%
-41.67%
Beta (5-Year)
4.214
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $0.72
200-day SMA
Sell
Level $0.91
Bollinger Bands (100)
Sell
Level 0.63 - 0.79
Chaikin Money Flow
Buy
Level 388.8M
20-day SMA
Sell
Level $0.71
Relative Strength Index (RSI14)
Sell
Level 46.50
ADX Line
Buy
Level 19.26
Williams %R
Buy
Level -84.6154
50-day SMA
Buy
Level $0.66
MACD (12, 26)
Sell
Level 0.01
25-day Aroon Oscillator
Buy
Level 64
On Balance Volume
Neutral
Level 5B

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-4.6717)
Sell
CA Score (Annual)
Level (-3.9059)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (5.4927)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Stock Forecast FAQ

In the current month, OCGN has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OCGN average analyst price target in the past 3 months is $6.75.

  • Where Will Ocugen Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Ocugen share price will rise to $6.75 per share over the next 12 months.

  • What Do Analysts Say About Ocugen?

    Analysts are divided on their view about Ocugen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ocugen is a Sell and believe this share price will drop from its current level to $4.00.

  • What Is Ocugen's Price Target?

    The price target for Ocugen over the next 1-year time period is forecast to be $6.75 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is OCGN A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Ocugen is a Buy. 2 of 2 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of OCGN?

    You can purchase shares of Ocugen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ocugen shares.

  • What Is The Ocugen Share Price Today?

    Ocugen was last trading at $0.67 per share. This represents the most recent stock quote for Ocugen. Yesterday, Ocugen closed at $0.67 per share.

  • How To Buy Ocugen Stock Online?

    In order to purchase Ocugen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

3 Recession-Proof ETFs to Invest in Now
3 Recession-Proof ETFs to Invest in Now

The U.S. gross domestic product (GDP) contracted 0.3% during the…

Is Butterfly Network the Best Small-Cap Stock?
Is Butterfly Network the Best Small-Cap Stock?

Brought to public trading by an SPAC merger in early…

Is Spotify a Millionaire-Maker Stock?
Is Spotify a Millionaire-Maker Stock?

Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 40x

Alerts

Buy
60
RGC alert for May 10

Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.

Buy
97
NGVC alert for May 10

Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.

Sell
38
ONTO alert for May 10

Onto Innovation [ONTO] is down 30.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock